Cooperative Agreement UM1AI191237
Award Date
7/24/25
Completion Date
5/31/30
Dollars Obligated
$2.9M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Cooperative Agreement
Place of Performance
New York, USA
Similar Awards
This Cooperative Agreement award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an individualized HIV cure strategy targeting the antibody-resistant component of the HIV reservoir. The $3,568,644 award, effective from July 7, 2025 to May 31, 2030, will support research to: Characterize the antibody-resistant HIV reservoir to identify sequences of resistant reservoir...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
This Project Grant award of $3,643,653 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports a consortium of researchers at the University of Pennsylvania to develop a chimeric antigen receptor (CAR) T-cell approach for controlling HIV replication and eliminating the viral reservoir. The key elements of the program include: 1) engineering HIV-specific T-cells with improved function and persistence,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $824,331 to the Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The project aims to investigate the early establishment and persistence of viral reservoirs in HIV/SIV infection, with a focus on the potential role of naive CD4+ T cells in...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...